Skip to content

Intranasal Ketamine Effectiveness in Reducing Intramuscular Injection Pain Before Sedation Among Children

Intranasal Ketamine Effectiveness in Reducing Intramuscular Injection Pain Before Sedation Among Children

Status
Completed
Phases
Phase 4
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT06139380
Enrollment
84
Registered
2023-11-18
Start date
2023-12-02
Completion date
2024-05-31
Last updated
2024-06-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Intranasal Ketamine, Pain

Brief summary

Hypothesis: Intranasal administration of ketamine would reduce the intramuscular pain of ketamine injection in children who undergo procedural sedation and analgesia in the emergency department.

Detailed description

Ketamine is a well-known medication in children's procedural sedation and analgesia. While it provides good analgesia along with sedation, its injection is painful and causes distress in children. Intranasal administration of Ketamine would reduce the intramuscular pain of ketamine injection in children who undergo procedural sedation and analgesia in the emergency department. This will also assess if intranasal administration would affect the depth of sedation and hospital length of stay of this group of patients.

Interventions

DRUGKetamine

This is medication which is commonly used for sedation in the emergency department. At the analgesic dose, this medication can be used to reduce the pain via other routes such as intranasal.

DRUGSterile water

Intranasal sterile water was administered via syringe.

Sponsors

Tehran University of Medical Sciences
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)

Masking description

We will blind medication administrator, care provider, and assessor in addition to the patients.

Intervention model description

2-group parallel double blind randomized controlled trial

Eligibility

Sex/Gender
ALL
Age
12 Months to 7 Years
Healthy volunteers
No

Inclusion criteria

• Children who need to undergo procedural sedation and analgesia

Exclusion criteria

* Weight over 33 Kg * No Consent from parents/patient * Needs immediate procedure due to patient's condition * Growth/mental retardation * Sensory deficit at the site of intramuscular injection

Design outcomes

Primary

MeasureTime frameDescription
Intramuscular injection painimmediately after Intramuscular injectionThis will be assessed at the time of injection using FLACC scale.

Secondary

MeasureTime frameDescription
Hospital stay duration1 hours on averageThis will be assessed using modified Ramsay's sedation scale.
Adverse effects1 hours on averageThis will be assessed using the standard definition of the adverse effects.

Countries

Iran

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026